Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + rivoceranib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + rivoceranib is an investigational combination therapy pairing an immune checkpoint inhibitor with an anti-angiogenic tyrosine kinase inhibitor (TKI). Adebrelimab is a humanized monoclonal antibody targeting Programmed cell death 1 ligand 1 (PD-L1), which works to restore anti-tumor T-cell activity. Rivoceranib (also known as apatinib) is a small-molecule TKI that selectively inhibits Vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking tumor angiogenesis. This combination is primarily being evaluated for the treatment of hepatocellular carcinoma (HCC), including its use in neoadjuvant or conversion therapy settings alongside hepatic arterial infusion chemotherapy (HAIC).
- Brand names
- HaiquAitan
- Other names
- SHR-1316 + apatinibSHR-1316 + rivoceranibHaiqu + Aitanadebrelimab plus rivoceranibapatinib
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on adebrelimab + rivoceranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + rivoceranib.